Maze Therapeutics, Inc., a biopharmaceutical company focused on developing precision medicines for renal, metabolic, and cardiovascular diseases, announced that CEO Jason Coloma, Ph.D., will present a ...
Monday - Friday, 2:00 - 3:00 PM ET In this article Maze Therapeutics has had a great run since its initial public offering in January — and CEO Jason Coloma is hoping that momentum continues as the ...
Investing.com - H.C. Wainwright reiterated its Buy rating and $60.00 price target on Maze Therapeutics (NASDAQ:MAZE) on Wednesday. The target represents a 32% upside from the current price of $45.34, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results